Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hematopoietic disorders in Down syndrome.

Literature DB >> 18787621

Hematopoietic disorders in Down syndrome.

Abstract

Patients with Down syndrome have an increased risk of developing various hematological disorders. In this article, the clinical characteristics and differential diagnosis of the hematological disorders associated with Down syndrome are reviewed, and the underlying molecular mechanisms discussed.

Entities: Disease Species

Keywords: Down syndrome; acute leukemia; myelodysplastic syndrome; transient myeloproliferative disorder

Year: 2008 PMID： 18787621 PMCID： PMC2480572

Source DB: PubMed Journal: Int J Clin Exp Pathol ISSN： 1936-2625

59 in total

1. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.

Authors: U Creutzig; J Ritter; J Vormoor; W D Ludwig; C Niemeyer; I Reinisch; B Stollmann-Gibbels; M Zimmermann; J Harbott
Journal: Leukemia Date: 1996-11 Impact factor: 11.528

2. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.

Authors: Yubin Ge; Alan A Dombkowski; Katherine M LaFiura; Dana Tatman; Ravikiran S Yedidi; Mark L Stout; Steven A Buck; Gita Massey; David L Becton; Howard J Weinstein; Yaddanapudi Ravindranath; Larry H Matherly; Jeffrey W Taub
Journal: Blood Date: 2005-10-25 Impact factor: 22.113

3. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis.

Authors: N J Karandikar; D B Aquino; R W McKenna; S H Kroft
Journal: Am J Clin Pathol Date: 2001-08 Impact factor: 2.493

4. Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21.

Authors: J M Smrcek; A A Baschat; U Germer; K Gloeckner-Hofmann; U Gembruch
Journal: Ultrasound Obstet Gynecol Date: 2001-05 Impact factor: 7.299

5. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.

Authors: James A Whitlock; Harland N Sather; Paul Gaynon; Leslie L Robison; Robert J Wells; Michael Trigg; Nyla A Heerema; Smita Bhatia
Journal: Blood Date: 2005-08-18 Impact factor: 22.113

6. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome.

Authors: J Lightfoot; J K Hitzler; A Zipursky; M Albert; P F Macgregor
Journal: Leukemia Date: 2004-10 Impact factor: 11.528

7. False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts.

Authors: S A Betz; K Foucar; D R Head; I M Chen; C L Willman
Journal: Blood Date: 1992-05-01 Impact factor: 22.113

8. Hematological abnormalities in newborn infants with Down syndrome.

Authors: M Miller; J M Cosgriff
Journal: Am J Med Genet Date: 1983-10

9. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.

Authors: A Zipursky; P Thorner; E De Harven; H Christensen; J Doyle
Journal: Leuk Res Date: 1994-03 Impact factor: 3.156

10. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.

Authors: Suzanne McElwaine; Claire Mulligan; Jürgen Groet; Monica Spinelli; Andrea Rinaldi; Gareth Denyer; Afua Mensah; Simona Cavani; Chiara Baldo; Franca Dagna-Bricarelli; Ian Hann; Giuseppe Basso; Finbarr E Cotter; Dean Nizetic
Journal: Br J Haematol Date: 2004-06 Impact factor: 6.998

13 in total

1. Transient leukemia in down syndrome: report of two cases with review of literature.

Authors: Alka V Gosavi; Prashant S Murarkar; Dhaneshwar N Lanjewar; Ravishankar V Ravikar
Journal: Indian J Hematol Blood Transfus Date: 2011-06-21 Impact factor: 0.900

2. Down syndrome with transient myeloproliferative disorder and Beta-thalassemia major.

Authors: Amit Garg; Ankur Singh; Mohanaraj Ramachandran; Seema Kapoor
Journal: Indian J Hematol Blood Transfus Date: 2014-01-22 Impact factor: 0.900

3. Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.

Authors: Manisha Gadgeel; Batool AlQanber; Steven Buck; Jeffrey W Taub; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal: Ann Hematol Date: 2021-04-23 Impact factor: 3.673

4. Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.

Authors: K Hussein; A Stucki-Koch; G Göhring; H Kreipe; M Suttorp
Journal: Leukemia Date: 2017-02-27 Impact factor: 11.528